This protocol addresses metastatic colon adenocarcinoma in a molecularly defined subgroup: proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours carrying a KRAS or NRAS mutation with confirmed BRAF wild-type status. Molecular profiling is central to identifying patients who fit this pathway.
Metastatic colon adenocarcinoma confirmed as pMMR/MSS, harbouring an NRAS gene mutation (or KRAS mutation), and with BRAF wild-type status. This combination of molecular findings defines both the patient population and the applicable treatment options.
For patients in this molecular subgroup whose disease has progressed through all available regimens, specific systemic agents — spanning combination and single-agent strategies — are recommended. Agent selection and sequencing depend on individual clinical factors detailed in the full structured protocol.